FDA's View On Generic Drug Label Carve-Outs
Law360 ( October 2, 2008, 12:00 AM EDT) -- The Camptosar decision clarifies questions surrounding whether and to what extent a generic-drug applicant must match each of the pioneer drug's labeled uses or whether certain uses of the pioneer drug can be carved out by the generic-drug applicant as a result of patent or statutory exclusivity bars....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.